title: Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.
abstract: The growth of MethA tumor was significantly inhibited by oral administration of the alpha-glucan SPR-901 in BALB/c (+/+) mice but not in nude mice. Mice treated orally with SPR-901 exhibited an augmentation of antigen-specific resistance against rechallenge with the tumor cells. The tumor-neutralizing activity of regional lymph node cells from MethA-bearing mice against the tumor was augmented by oral administration of SPR-901. The tumor-neutralizing activity of lymph node cells from SPR-901-treated mice mainly appeared in Lyt2+ cells. Furthermore, lymphokine-activated killer activity of these cells was enhanced by administration of SPR-901. The antitumor effect of SPR-901 was abrogated in mice depleted of either L3T4+ or Lyt2+ cells, and in cyclosporin-A-treated mice. These results suggest that Lyt2+ cells are important effector cells in MethA-bearing mice orally administered SPR-901 and that functional exertion of both Lyt2+ and L3T4+ T cells is necessary for the antitumor effect of orally administered SPR-901 in vivo.
authors.affiliation: Pharmaceutical Research Laboratories, Sapporo Breweries Ltd., Shizuoka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Miyazaki
authors.forename: S
authors.initials: S
authors.lastname: Takeo
authors.forename: K
authors.initials: K
authors.lastname: Nomoto
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshikai
mesh_terms: D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D000950:Antigens, Ly / Q000276:immunology; D000970:Antineoplastic Agents; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016572:Cyclosporine / Q000494:pharmacology; D005260:Female; D005936:Glucans / Q000008:administration & dosage*; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008198:Lymph Nodes / Q000166:cytology; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D012513:Sarcoma, Experimental / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000950:Antigens, Ly; D000970:Antineoplastic Agents; D005936:Glucans; C065495:rice bran saccharide; D016572:Cyclosporine